BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN), ARCA biopharma, Inc. (Nasdaq - ABIO)
BALA CYNWYD, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Shockwave Medical, Inc. (Nasdaq – SWAV)
Under the terms of the Merger Agreement, Shockwave will be acquired by Johnson & Johnson (NYSE - JNJ). Johnson & Johnson will acquire all outstanding shares of Shockwave common stock for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired. The investigation concerns whether the Shockwave Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration offers fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/shockwave-medical-inc-nasdaq-swav/.
Apartment Income REIT Corp. (NYSE - AIRC)
Under the terms of the agreement, AIR Communities will be acquired by Blackstone (NYSE - BX). Under the terms of the transaction, Blackstone Real Estate Partners X will acquire all outstanding shares of AIR Communities common stock for $39.12 per share in cash, implying a transaction value of approximately $10 billion. The investigation concerns whether the AIR Communities Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration offers fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/apartment-income-reit-corp-nyse-airc/.
Model N, Inc. (NYSE – MODN)
Under the terms of the agreement, Model N will be acquired by Vista Equity Partners (“Vista”). Vista will acquire all outstanding shares of Model N common stock for $30.00 per share in cash, implying a transaction value of approximately $1.25 billion. The investigation concerns whether the Model N Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration offers fair value to the Company’s shareholders. For example, the deal consideration is below the 52-week high of $35.96 for the Company’s shares.
Additional information can be found at https://www.brodskysmith.com/cases/model-n-inc-nyse-modn/.
ARCA biopharma, Inc. (Nasdaq - ABIO)
Under the terms of the agreement, ARCA will be acquired by Oruka Therapeutics (“Oruka”). Pre-merger ARCA stockholders are expected to own approximately 2.38% of the combined company and pre-merger Oruka stockholders are expected to own approximately 97.62% of the combined company. The investigation concerns whether the ARCA Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to ARCA stockholders in the combined company.
Additional information can be found at https://www.brodskysmith.com/cases/arca-biopharma-inc-nasdaq-abio/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn